Examkin

Soru

Zorluk: Çok zorOrdering Laboratory Tests

A 29-year-old woman is evaluated in the hospital for sudden-onset pleuritic chest pain and dyspnea. CT pulmonary angiography confirms an acute pulmonary embolism, and she is immediately started on a continuous intravenous unfractionated heparin infusion. Her past medical history is significant for three consecutive spontaneous first-trimester abortions. Vital signs are temperature 37.1°C (98.8°F), blood pressure 118/76 mmHg, pulse 102/min, and respirations 18/min. She is hemodynamically stable. The medical team strongly suspects an underlying antiphospholipid syndrome (APS) or other inherited thrombophilia. Which of the following is the most appropriate strategy for the diagnostic laboratory evaluation of this patient's suspected hypercoagulable state?

  1. Measure anticardiolipin antibodies and anti-beta-2 glycoprotein-I antibodies now; defer lupus anticoagulant testing until after heparin therapy is discontinuedCevap
  2. B
    Measure lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2 glycoprotein-I antibodies immediately to establish a definitive diagnosis before discharge
  3. C
    Measure antithrombin, protein C, and protein S activity levels during this admission to rapidly rule out the most common inherited thrombophilias
  4. D
    Order a transesophageal echocardiogram to evaluate for Libman-Sacks endocarditis prior to obtaining any hypercoagulability laboratory panels
  5. E
    Perform a prolonged mixing study with normal pooled plasma immediately to definitively differentiate a factor deficiency from a circulating inhibitor

Cevap

The correct strategy is to measure anticardiolipin and anti-beta-2 glycoprotein-I antibodies now, but defer lupus anticoagulant testing until after the patient is off heparin therapy.
The correct strategy is to measure anticardiolipin and anti-beta-2 glycoprotein-I antibodies now, but defer lupus anticoagulant testing. The diagnosis of antiphospholipid syndrome (APS) requires at least one clinical criterion (e.g., vascular thrombosis or pregnancy morbidity, such as this patient's recurrent miscarriages) and at least one laboratory criterion. The laboratory criteria include positive anticardiolipin antibodies, positive anti-beta-2 glycoprotein-I antibodies, or the presence of a lupus anticoagulant. Anticardiolipin and anti-beta-2 glycoprotein-I antibodies are measured via solid-phase enzyme-linked immunosorbent assays (ELISA) and are not affected by acute thrombosis or concurrent anticoagulant therapy. Therefore, they can be accurately measured during the acute admission. However, the lupus anticoagulant is detected using phospholipid-dependent clotting assays (such as the dilute Russell viper venom time or aPTT). Because unfractionated heparin exerts its anticoagulant effect by prolonging these exact clotting times, performing a lupus anticoagulant assay while a patient is on heparin will result in a false-positive finding. Therefore, testing for the lupus anticoagulant must be deferred until the patient is no longer receiving heparin therapy.

Adım Adım Çözüm

1
Identify the patient's likely underlying condition based on the clinical presentation.
The patient has an acute venous thromboembolism and a history of recurrent early miscarriages, which is highly suspicious for antiphospholipid syndrome (APS).
Recognizing the syndrome is required to determine which specific laboratory tests are indicated (lupus anticoagulant, anticardiolipin antibodies, anti-beta-2 glycoprotein-I antibodies).
2
Analyze the laboratory methodology for each required diagnostic test.
Anticardiolipin and anti-beta-2 glycoprotein-I antibodies are measured via ELISA. Lupus anticoagulant is measured via phospholipid-dependent clotting assays (e.g., dRVVT or aPTT).
Different assay methodologies respond differently to systemic anticoagulation and acute inflammatory states.
3
Determine the impact of the patient's current treatment (unfractionated heparin) on the indicated laboratory assays.
Heparin prolongs aPTT and dRVVT, which will cause false-positive results in the lupus anticoagulant assay. Heparin does not interfere with solid-phase ELISAs.
This pathophysiologic understanding dictates the precise sequencing of laboratory orders to avoid diagnostic errors.
4
Formulate the optimal test sequencing plan.
Order the ELISA-based tests immediately and defer the clot-based lupus anticoagulant assay until the heparin is discontinued.
This maximizes diagnostic efficiency while ensuring laboratory results are accurate and interpretable.

Anahtar Kavram

In patients with suspected antiphospholipid syndrome, solid-phase ELISAs (anticardiolipin and anti-beta-2 glycoprotein-I antibodies) can be measured during acute thrombosis and anticoagulation, whereas clot-based assays (lupus anticoagulant) must be deferred due to false-positive interference from heparin.
Bu soruyu puanla

Konular

Ordering Laboratory Tests

Bu konudan daha fazla soru